Roche Diagnostics Operations, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Norbert Wild

Johann Karl

Herbert Andres

Werner Zolg

Veit Peter Grunert

Michael Tacke

Wolfgang Rollinger

Markus Roessler

Julia Riedlinger

Friedemann Krause

Marie-Luise Hagmann

Viet Peter Grunert

Marie Luise Hagmann

Ursula Garczarek

Michael Pfeffer

Michael Thierolf

Andrea Geistanger

Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Secernin-1 as a marker for cancer

Disclosed is a method for assessing a severity of rheumatoid arthritis. The method involves measuring in a patient sample a concentration of anti-cyclic citrullinated peptides (anti-CCP) and serum amyloid A, combining the concentrations determined to obtain a combined value, and comparing the combined value to a cut-off value established from a reference population. In another method, a marker selected from the group consisting of C-reactive protein (CRP), interleukin 6 (IL-6), S100 protein, osteopontin, rheumatoid factor (RF), matrix metalloprotease 1 (MMP-1), matrix metalloprotease 3 (MMP-3), hyaluronic acid, and soluble CD14 (sCD14) may also be determined along with the anti-CCP and serum amyloid A.

Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid A

Disclosed is an in vitro method aiding in the further assessment of patients suffering from rheumatoid arthritis. The method especially is used in assessing whether an RA patient is at risk of disease progression. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of at least C-reactive protein (CRP) and interleukin-6 and correlating the concentrations determined to the likelihood of an underlying rapidly progressing form of RA. A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. The invention also relates to the use of a marker panel comprising C-reactive protein and interleukin-6 in the assessment of a patient with rheumatoid arthritis and it teaches a protein array device and kit, respectively, for performing the method of the invention.

Assessing risk of disease progression in rheumatoid arthritis patients

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and serum amyloid A and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and serum amyloid A and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and serum amyloid A in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Combined measurement of anti-CCP and serum amyloid A to assess rheumatoid arthritis

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and interleukin 6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and interleukin 6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and interleukin 6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6

Growing community of inventors

Geretsried/Gelting, Germany

Norbert Wild